Imara Inc. IMRA
We take great care to ensure that the data presented and summarized in this overview for IMARA Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IMRA
Top Purchases
Top Sells
About IMRA
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2?related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Transactions at IMRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 27
2024
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,250
-90.48%
|
$131,250
$25.08 P/Share
|
|
Nov 27
2024
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,250
+50.0%
|
$10,500
$2.48 P/Share
|
|
Oct 28
2024
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,250
-94.8%
|
$175,000
$28.8 P/Share
|
|
Oct 28
2024
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
$12,500
$2.48 P/Share
|
|
Oct 18
2024
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
814
-100.0%
|
$24,420
$30.0 P/Share
|
|
Oct 18
2024
|
Benjamin Hohl CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
814
+50.0%
|
$1,628
$2.48 P/Share
|
|
Oct 18
2024
|
Samuel Kintz PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
924
-0.09%
|
$27,720
$30.0 P/Share
|
|
Oct 18
2024
|
Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
847
-0.08%
|
$25,410
$30.0 P/Share
|
|
Oct 18
2024
|
Anish Patel CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Indirect |
716
-0.21%
|
$21,480
$30.0 P/Share
|
|
Oct 18
2024
|
Helen Louise Collins CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
816
-100.0%
|
$24,480
$30.0 P/Share
|
|
Oct 18
2024
|
Helen Louise Collins CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
816
+50.0%
|
$1,632
$2.48 P/Share
|
|
Oct 18
2024
|
Richard A. Heyman |
SELL
Open market or private sale
|
Indirect |
753
-2.7%
|
$22,590
$30.0 P/Share
|
|
Oct 18
2024
|
Richard A. Heyman |
SELL
Open market or private sale
|
Direct |
817
-0.66%
|
$24,510
$30.0 P/Share
|
|
Oct 15
2024
|
Richard A. Heyman |
SELL
Open market or private sale
|
Direct |
1,270
-1.01%
|
$34,290
$27.67 P/Share
|
|
Oct 09
2024
|
Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
37,878
-1.8%
|
$1,060,584
$28.32 P/Share
|
|
Oct 09
2024
|
Samuel Kintz PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
16,710
-0.82%
|
$467,880
$28.3 P/Share
|
|
Oct 08
2024
|
Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
13,267
-0.62%
|
$371,476
$28.24 P/Share
|
|
Oct 08
2024
|
Rahul D. Ballal |
SELL
Open market or private sale
|
Direct |
10,420
-31.81%
|
$291,760
$28.17 P/Share
|
|
Oct 08
2024
|
Rahul D. Ballal |
BUY
Exercise of conversion of derivative security
|
Direct |
10,420
+14.6%
|
$125,040
$12.6 P/Share
|
|
Oct 08
2024
|
Samuel Kintz PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
13,267
-0.64%
|
$371,476
$28.23 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 487K shares |
|---|
| Open market or private sale | 4.18M shares |
|---|